Available Online at www.ijpba.in

International Journal of Pharmaceutical and Biological Science Archive 1 (1) 2013, 18-21

SHORT COMMUNICATION ARTICLE

INNOVATIONS IN NON- INTRUSIVE PRENATAL DIAGNOSTIC INVESTIGATION

Pramod Singh Khatri[1]*, Madhulika Kabra[2], Sumit Kumar[3]

[1]PhD. Scholar, Shri Venkateshwara University, Gajraula, Uttar Pradesh, India

[2]Professor of Pediatrics, ALL India Institute of Medical Science, Delhi, India

[3]Associate Professor, IAMR, Gaziabad, India

Received 10 May 2013; Revised 15 May 2013; Accepted 30 May 2013

ABSTRACT

The Human Genome Project was a prime illustration of how interdisciplinary coordinated effort around major public foundations, the educated community, and the private sector may as well function. Regardless of this, public familiarity with any profit from the foods grown from the ground of the human genome and the advances it brought forth is constrained.

KEY WORDS: prenatal diagnosis, NGS, Amniocentesis, CVS, LDT, MPS, Aneuploidy

INTRODUCTION:

The Human Genome Project was a prime illustration of how interdisciplinary coordinated effort around major public foundations, the educated community, and the private sector may as well function. Regardless of this, public familiarity with any profit from the foods grown from the ground of the human genome and the advances it brought forth is constrained.

A handful of begin up genomic associations made vainglorious guarantees about how the resulting wave of genomic informative data might prompt a transformation in tailor-made drugs and personalized medications. Twelve years after the fact the assurance of a slew of novel medications dependent upon targets determined from the human genome venture has yet to be conveyed.

Although tailor-made medicines have not yet emerged on a broader scale, the devices and advances that rose throughout or ensuing to the genome project are having a developing effect on the advancement of novel analytic tests. Such tests might at last convey on the assurance of personalized medicine.



Figure: 1

*Corresponding author: Pramod Khatri | Email: pramodsinghkhatri@gmail.com

Till date, next –generation sequencing (NGS) has committed altogether to biomedical research fundamentally through the inconceivable measure of information that it processes in a generally less time. Having the ability to create this information considerably more cost -efficiently and from larger sample sets than a decade prior aide's researchers better comprehend particular hereditary and epigenetic patrons to infection and to clarify cellular forms and natural pathways underlying infection etiology. Notwithstanding, proper clinical studies are crucial to decipher these findings into either analytic or restorative tools and demonstrate their viability in patient care and medical practice. This clinical validation stage is perplexing and has advanced more gradually. Yet, there are an expanding number of exceptional illustrations of enhanced remedial methodologies with genotype-specific activities.

Alongside pharmacogenomics, the field of cancer genomics has possibly profited the most from the quick pace of advancements in sequencing. NGS-based genomic profiling considers extensive finding of point transformations, insertions/deletions, duplicate number variations and rearrangements, and if fundamental, can furnish profound dissection when exceptionally heterogeneous material is the main specimen source. These proficiencies are driving the recognizable proof of focused on cancer therapies, the advancement of biomarkers and possibly indicative tests for suitable choice of the curative choice. Today, there are an expected 500 compounds being developed focusing over 100 genes/proteins as well as a set of actionable transformations that drive response and imperviousness to a specific medication. Notwithstanding the resulting strength of NGS in the discovery stage and expanded use throughout predinical stages, it has not yet discovered as a vast use in routine clinical diagnostics.

We depict here what might be acknowledged the first accurate high-throughput requisition of NGS to the advancement and commercialization of symptomatic tests in the field of fetal/maternal medicine. Of specific note is the latest launch of high precision molecule tests that take into consideration the first run through the immediate non-intrusive recognition of fetal aneuploidies, for example trisomies of chromosomes 21, 18 or 13, which underlie, separately, Down, Edward, and Patau syndromes.

UNSAFE STRATEGIES OF PRENATAL SCREENING:

A noteworthy number of gestation deliver an embryo with a chromosomal distortion prompting a possibly weakening hereditary disorder, reflected for instance at the DNA level as extra chromosomal material (T21, T18, and T13 being the more regular), translocations, deletions, or micro deletions of numerous megabases of DNA (e.g. diGeorge syndrome). Of these, trisomy 21, the underlying causality of Down syndrome is the most well-known, happening with a recurrence of ~1:690 in live births. In spite of the fact that portrayed phenotypically in 1866, it was not until 1959, that Down syndrome was illustrated by histological methods to result from embryo carrying a third duplicate of chromosome 21. In no time thereafter, intrusive methods amniocentesis or chorionic villus examining (CVS)—were offered, such that aspiration of amniotic liquid or a modest example of placental tissue from a pregnant mother could be utilized in a karyotyping test. These tests, did between 10-20 weeks of gestation, are exceptionally precise (sensitivity & specificity of >99%), however the intrusive nature of the technique makes incredible fidgetiness to the patient, danger of tainting and an expected 1:200 to 1:100 risk of a fetal misfortune. Regardless, adjusting the risk profit, the ACOG prescribed in 2007,[1] that amniocentesis or CVS be offered for conclusive finding to all ladies with an extended risk for a fetal trisomy as an outcome of any of: maternal age (>35 at term), past personnel or family history of a fetal aneuploidy or comes about because of an earlier biochemical or ultrasonography test suggestive of a fetal aneuploidy. There were nearly 200,000 such tests completed within approx. 750,000 high-risk pregnancies in the United States in 2007.

NONINVASIVE TESTING OF PRENATAL SCREENING:

It was not until 1997 that it was understood that fetal DNA (and RNA) in the manifestation of minor apoptotic particles is available in maternal blood as circulating cell free fetal DNA (ccff DNA).[2] This finding accelerate the investigation of different routines that may utilize ccff RNA or DNA as analytes for pre-birth hereditary tests. These tests might be dependent upon a risk free blood draw instead of the more risk inclined "highest level" amniocentesis or CVS obtrusive methods.

While various assuring methods breaking down DNA, RNA, or epigenetic markers with an assortment of advances running from mass spectrometry to advanced PCR and sequencing have been depicted, a definitive test has been to describe and advance a test philosophy that is handy, correct, and cost -effective.

Despite the exceptional precision of histological karyotyping of a specimen acquired by either amniocentesis or CVS, the innate danger of these methods has been driving examination towards noninvasive results (i.e. blood-based or imaging). Numerous convenient protein biomarkers show in maternal blood has been distinguished and is considerably utilized as a part of screening standards in the India. Ultrasonography in continually enhancing configurations has likewise been

added to the armamentarium of the OB/GYN, however indeed, when consolidated with serum screening the general effect still prompts an inadmissibly flat combo of sensitivity and specificity. This shows as numerous false positive results around the minor number of accurate positive outcomes. Given that generally positives tests continue to an absolute obtrusive technique for affirmation, it is assessed that >95% of the 200,000 intrusive methods completed in the India every year might be unnecessary if a high-accuracy non-obtrusive test were accessible.

Massively parallel "shotgun" sequencing (MPS) has indicated potential as a technique to use ccff DNA in maternal plasma or serum as an analyte for fetal aneuploidy detection.[3, 4] Although ensuring, conclusions as to this present reality clinical applicability of these early studies were restricted by the moderately little number of case/control specimens investigated and the overwhelming cost of sequencing instrumentation and reagents around them. Regardless, these studies incited some associations to further investigate the business potential of NGS as the foundation for advancing a Laboratory developed test (LDT).

STAGES UNDER ATTENTION:

While likelihood studies have been completed conclusively on the most part of the currently accessible NGS stages, the Illumina HiSeq has turned out to be the present stage of decision for the associations Sequenom Inc., Verinata Inc., Ariosa Inc., and Natera Inc.—that have started analytic tests in the United States for non-intrusive aneuploidy testing. The choice of the HiSeq as the instrument of decision most likely identifies with the development of the instrument at the time then clinical acceptance was performed, the generally high-limit (information indicates and also number of examples for every run), and sufficient time to result for most labs. The HiSeq is prone to be subplanted by additional propelled instrumentation and reagents inside two years.

DISTINGUISHING ANEUPLOIDY:

Throughout pregnancy 5% to 20% of the cell free DNA in a maternal blood example is of fetal derivation (ccff DNA). The rule behind a MPS methodology is in this way: if secluded, enhanced, and sequenced as short peruses that could be adjusted against the human genome, all flowing cell free DNA fragments (both maternal and fetal) in a maternal specimen might be relegated to the chromosome of origin. Gave a sufficient number of interesting peruses (more than 4 to 10 million) are acquired; the relative number of fragments acquired for every chromosome might be utilized to confirm if a mother is conveying a euploid or aneuploid baby. For instance, on account of a mother carrying a T21 baby, MPS sequencing of the consolidated maternal and fetal ccff DNA will show an overrepresentation of chromosomal material that twitches from chromosome 21.

Catching up on efficacious early analytical studies, certain business research facilities saw fit to go beyond commanded diagnostic test acceptance and undertook large scale clinical acceptances studies before starting a LDT. In a blinded, nested case-control study that utilized specimens from over 2,200 high risk pregnancies, one such study (that incorporated 212 cases of T21 affirmed by amniocentesis), reported a sensitivity of 99.1% and a specificity of 99.9%, with a no outcome rate of 0.8%.[5] These and ensuing smaller clinical validation studies have resoundingly demonstrated the utility of NGS in a clinical setting. [6-8] A flash of the innovations full competencies has been demonstrated recently with the remaking of the entire fetal genome from cfDNA of the maternal plasma of a pregnant woman.[9, 10]

RELATING NGS TO DIAGNOSTICS:

An expected 200,000 to 300,000 LDT will be performed in the United States in 2013, under the brand names: MaternityT21 PLUS, Harmony, Verify, and Panorama. In the first place ready in late 2011, no less than 60,000 such tests were performed in 2012. Presently, guidelines from some conglomerations have proposed the utilization of such tests, all performed on NGS stages, in ladies at high risk for T21 and T18. It is likely that broader test substance (T13, sex aneuploidies, sex determination for medicinal purposes, for example X-Linked recessive disease, micro deletions. And so on.) And broader use in all pregnancies could be endorsed in the following year or two.

CONCLUSIONS:

While talk of the sub $1,000 genome has been hanging buzzing around for at some point, a few associations, for example Ilmn, Complete Genomics, BGI, and others have been putting forth entire genome sequencing for $5-10,000 for past year or two. From either a business or clinical viewpoint, it is difficult to judge the degree of lifelong interest for this administration, even as it turns into moderate to a considerable number. Outside that coliseum and at the present time, the two generally ensuring requisitions for NGS (and future versions) seem, by all accounts, to be in oncology and prenatal heredity.

The fast organization of NGS for noninvasive pre-birth heredity might seem, by all accounts, to be utilizing a sledge to break a nut. A stiffer test will be pervasive provision of NGS to entire cancer genome sequencing in a

clinical setting. At the present pace of development it won't be much sooner than NGS turns into a crux stage for sidekick diagnostics in oncology; increasing if not displacing immunohistochemical, Fish, and PCR biomarker detection systems. Expansive access may require yet a further change in the expense and convey capacity of sequencing stages.

Beyond oncology, there is liable to be a huge future for NGS in the revelation and advancement of epigenetic markers in chronic maladies, particularly in the immune system and neurology area. Such markers are painfully demanded to give sharper devices whatsoever phases of drug development, from drug discovery to exploratory and critical trials.

COMPETING INTERESTS:

The authors declare that they have no competing interests

REFERENCES:

1. ACOG Practice Bulletin No. 77. Screening for Fetal Chromosomal Abnormalities. *Obstet and Gynecol*, 2007.
2. Fan, C, Blumenfeld, YJ et al. Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood. *PNAS*, 2008.
3. Kitzman, JO, Snyder, MW et al. Noninvasive Whole-Genome Sequencing of a Human Fetus. *Sci Transl Med*, 2012.
4. Lo, YM, Chan, KC et al. Maternal Plasma DNA Sequencing Reveals the Genome-Wide Genetic and Mutational Profile of the Fetus. *Sci Transl Med*, 2010.
5. Norton, M, Brar, H et al. Non-Invasive Chromosomal Evaluation (NICE) Study: Results of a Multicenter, Prospective, Cohort Study for Detection of Fetal Trisomy 21 and Trisomy 18. *Am J Obstet Gynecol*., 2012.
6. Lo, YM, Corbetta, N. et al. Presence of fetal DNA in maternal plasma and serum. *Lancet*, 1997.
7. Chiu, RW, Chan, KC et al. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. *PNAS*, 2008.
8. Palomaki, GE, Kloza, EM et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. *Genet Med*. 2011
9. Bianchi, DW, Platt, LD et al. Genome-Wide fetal aneuploidy detection by maternal plasma DNA sequencing. *Obstet Gynecol*., 2012.
10. Zimmermann, B, Hill, M et al. Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X and Y, using targeted sequencing of polymorphic loci. *Prenatal Diagnosis*, 2012.

